Active Research Protocols
- 10-C-0052 – Phase II Study of Dose-Adjusted EPOCH+/-Rituximab in Adults with Untreated Burkitt Lymphoma, c-MYC Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma
- 93-C-0133 – Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Adults and Children with Previously Untreated Patients with Aggressive Non-Hodgkin's Lymphoma
NOTE: PDF documents require the freeAdobe Reader.
This page was last updated: January 24, 2014